All In Biotech

Drug Trial Radar · NCT05462717

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

222

Planned (sponsor's estimate)

Start

Sep 19, 2022

Primary completion

Mar 31, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
First posted
Jul 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma
  • Advanced Solid Tumor

Interventions

  • RMC-6291Drug

    Oral tablet once or twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: up to 3 years
  2. Dose Limiting ToxicitiesTime frame: The first 21 days (i.e. Cycle 1)

Locations

64 sites in 13 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Springdale, Arkansas

  • UC Irvine Cancer Center

    Orange, California

  • UC Davis Cancer Center

    Sacramento, California

  • UCSF

    San Francisco, California

  • University of Miami School of Medicine Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • American Oncology Partners of Maryland

    Bethesda, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • MSK Cancer Center

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Tennessee Oncology

    Nashville, Tennessee

  • Next Oncology

    San Antonio, Texas

  • START

    San Antonio, Texas

  • Next Oncology Virginia

    Fairfax, Virginia

  • Southside Cancer Care Centre

    Sydney, New South Wales, Australia

  • Peninsula & South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia

  • Austin Health, Olivia Newton-John Cancer Research & Wellness Centre

    Heidelberg, Victoria, Australia

  • South West Health Care

    Warrnambool, Victoria, Australia

  • NH Hospital a.s.

    Hořovice, Czechia

  • Klinika onkologie a radioterapie, Fakultni Nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Onkologicka klinika, Fakultni Nemocnice Olomouc

    Olomouc, Czechia

  • ICO

    Angers, France

  • CHU Bordeaux Hospital Saint-Andre

    Bordeaux, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Léon Bérard

    Lyon, France

  • CHU Nantes

    Nantes, France

  • ICANS

    Strasbourg, France

  • S.C. Oncologia Falck, Dipartimento Ematologia ed Oncologia Niguarda Cancer Center

    Milan, Italy

  • Istituto Europeo Oncologico

    Milan, Italy

  • Istituto Nazionale Tumori Fondazione G. Pascale

    Naples, Italy

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    Orbassano, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Centro Ricerche Cliniche di Verona s.r.l.

    Verona, Italy

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • Sarawak General Hospital

    Kuching, Malaysia

  • Instytut MSF Sp zoo

    Lodz, Poland

  • Med - Polonia Sp. z o. o.

    Poznan, Poland

  • Narodowy Instytut Onkologii

    Warsaw, Poland

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.